louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07013383: I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy
Official title: The Effect of the "I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy" Program on Recycling Behaviors of Secondary School Students
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Recycling
Behavior Change
Student
Lead sponsor: Suleyman Demirel University
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 86
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The research will be conducted to determine the effect of "I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy" program on secondary school students' recycling behaviour.

Detailed description: Recycling is crucial for environmental health as it plays a significant role in the protection of the environment, the conservation of natural resources, and the reduction of energy consumption. The Sustainable Development Goals (SDGs) are fundamentally centered around the themes of water management, energy sustainability, and responsible consumption and production practices. Without proactive measures to safeguard environmental health, the world is likely to encounter significant challenges related to water security, food supply, and the sustainability of natural resources in the future.

The study intervention was meticulously formulated on the basis of the Planned Behaviour Theory, encompassing a training programme focused on secondery school students' recycle behaviour. The training program includes topics such as environmental pollution, recycling behaviors, and the protection of natural resources and ecosystems. In addition, the program incorporates activities such as games, puzzle, brainstorming sessions, and the creation of painted cloth bags.

Eligibility criteria: Inclusion Criteria:

Being 10-14 years old and attend the school where the study is being conducted, Voluntarily agree to take part in the research,

Exclusion Criteria:

Having received previous education on environmental health

Primary outcomes:
measure: Recycling Behavior Scale
timeFrame: T0 (Pre-test) T1 (15 days after the end of the procedure)
Secondary outcomes:
measure: Recycling behavior predictive
timeFrame: T0 (Pre-test) T1 (15 days after the end of the procedure)
Other outcomes:
Locations:
city: Isparta
country: Turkey
facility: Isparta
Study officials:
References:
Clinical trial NCT04214483: A Pilot Study to Explore the Role of Gut Flora in Acne
Official title: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Acne
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Acne
Acne Vulgaris
Acne Keloidalis
Acne Keloid
Acne Conglobata
Acne Rosacea
Acne Inversa
Acne Cystic
Acne Pomade
Acne Indurata
Acne Papular
Acne Tropica
Acne Urticata
Acne Fulminans
Acne Follicular
Acne Tropicalis
Acne Detergicans
Acne Iodide
Acne Varioliformis
Lead sponsor: ProgenaBiome
Sponsor class: OTHER
First posted: 2020-01-02
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acne

Brief summary: This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed description: The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to acne.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

   a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent
2. Male or female of all ages.
3. Diagnosis of acne by a physician

Exclusion Criteria:

1. Refusal to sign informed consent form
2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
3. Postoperative stoma, ostomy, or ileoanal pouch
4. Participation in any experimental drug protocol within the past 12 weeks
5. Treatment with total parenteral nutrition

Primary outcomes:
measure: Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing
timeFrame: Three years
Secondary outcomes:
Other outcomes:
Locations:
city: Ventura
country: United States
facility: ProgenaBiome
state: California
Study officials:
affiliation: ProgenaBiome
name: Sabine Hazan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04587583: WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers
Official title: WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Dementia
Caregiver
Memory Disorders
Alzheimer Disease
Behavioral Symptoms
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
First posted: 2020-10-14
Enrollment: 19
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This research will test the WeCareAdvisor tool for family caregivers of military veterans with dementia to help caregivers assess, manage and track behavioral symptoms and their contributing factors (e.g., pain, sleep disturbance), and that provides tailored strategies for in-home, medication-free behavior management. 60 caregiver-person with dementia dyads will be recruited (30 Treatment Group, 30 Wait-List Control Group).


Eligibility criteria: Inclusion Criteria:

Eligible caregivers must:

* Be the primary caregiver of a military veteran with dementia for at least 6 months and planning to remain the primary caregiver for the next 2 months
* Currently living with the person they are caring for (care recipient)
* Comfortable utilizing technology (e.g. computers, tablets, the internet)
* Have access to the internet and a computer or tablet device
* Plans to live in the area for the duration of the study

Care recipients (military veteran living with dementia) must:

* Exhibit at least one or more behavioral symptoms (any behavior at any frequency)
* Receiving psychotropic medication or cognitive enhancers will not exclude the care recipient.
* Have a clinical diagnosis of dementia (any type) per caregiver report.
* Be a military veteran.

Exclusion Criteria:

* Inability to read, speak or understand English
* Lack of regular access to a telephone, internet, technology (tablet or computer)
* Caregiver is unable to use a computer or tablet
* Person with dementia is not a military veteran

Primary outcomes:
measure: Change in Caregiver Stress
timeFrame: Baseline to 2 months
measure: Change in Caregiver Confidence in Managing Problematic Behavior
timeFrame: Baseline to 2 months
measure: Change in Caregiver Upset
timeFrame: Baseline to 2 months
Secondary outcomes:
measure: Change in Caregiver Communication
timeFrame: Baseline to 2 months
Other outcomes:
measure: Ease of Use of the WeCareAdvisor Tool
timeFrame: 1 month after using WeCareAdvisor tool
measure: Usefulness/ Perceived Benefit of the WeCareAdvisor Tool
timeFrame: 1 month after using WeCareAdvisor tool
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Frederic C Blow, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04631783: Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea.
Official title: Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obstructive Sleep Apnea
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2020-11-17
Enrollment: 3000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with polysomnography during 2016/1/1-2019/12/31

Brief summary: This observational survey with retrospective follow-up is designed to study the daytime sleepiness based on Epworth Sleepiness Scale a good way or not to assess Taiwanese with suspected obstructive sleep apnea.

Detailed description: Daytime sleepiness (DS) is a complicated clinical problem, often indicating a serious underlying physiological abnormality and associated with higher prevalence of comorbid conditions such as diabetes, myocardial infarction, and stroke. Daytime sleepiness is also the cardinal symptoms of obstructive sleep apnea. How to identify the high risks patients with obstructive sleep apnea for further polysomnography is a difficult problem for doctors in out-patient department. Different methods have been proposed for measuring sleepiness and the Epworth sleepiness scale (ESS) is the measure of sleepiness most commonly used in sleep research and clinical settings.

However, whether Epworth sleepiness scale is a good tool with high predictive value of obstructive sleep apnea is not evaluated in the population of Taiwanese. This observational study is set up to document these practices.

Eligibility criteria: Inclusion Criteria:

* patients with polysomnography during 2016/1/1-2019/12/31

Exclusion Criteria:

* age under 20 year-old
* incomplete polysomnography
* incomplete chart information
* patients with narcolepsy
* patients with previous diagnosed with obstructive sleep apnea, including already patients with obstructive sleep apnea under treatment

Primary outcomes:
measure: Correlation between Epworth sleepiness scale and the severity of obstructive sleep apnea
timeFrame: baseline (The Epworth sleepiness scale was completed just before the polysomnography)
measure: The specificity and sensitivity of Epworth sleepiness scale for obstructive sleep apnea
timeFrame: Baseline (The Epworth sleepiness scale was completed just before the polysomnography)
Secondary outcomes:
measure: Questionnaire: If there are some specific symptoms as a tool with better sensitivity or specificity than Epworth sleepiness scale for obstructive sleep apnea
timeFrame: Baseline
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04473183: Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota
Official title: Epidemiologic Assessment of SARS-CoV-2 Prevalence in Minnesota
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Covid19
SARS-CoV Infection
SARS-CoV-2
Corona Virus Infection
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2020-07-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Group 1 are members of general healthy population. Group 2 are medical residents. Group 3 are individuals who test positive for HIV infection.

Brief summary: The purpose of this epidemiologic study is to estimate the prevalence and incidence of anti-SARS-CoV-2 antibodies in at-risk, exposed, affected populations. The study will also estimate the risk of SARS-CoV-2 exposure in target population.

Detailed description: This study is not for real-time diagnostic purposes, guidance for patient care, or the development of a diagnostic test. The research tests performed for this study will not be prioritized over clinical care samples, that research samples will be batched and tested after clinical care samples. This study is a population-based epidemiologic analysis of prevalence of various groups of persons.

Group (1) general healthy population. People 18 years of age and older that have not tested positive for SARS-CoV-2 and who have not sought medical help in the previous 4 months.

Group (2) Medical School Residents , 18 years of age and older that have not tested positive for SARS-CoV-2 Group (3) Individuals who are HIV positive. People 18 years of age and older that have not tested positive for SARS-CoV-2

Eligibility criteria: Inclusion Criteria:

* Participants in Group 1 (General Healthy Population) must have no known exposure to SARS-CoV-2 and have not sought medical help in the previous 4 months for SARS-CoV-2-related symptoms
* Participants in Group 2 must be currently enrolled in a medical residency program
* Participants in Group 3 must currently test positive for HIV infection

Exclusion Criteria:

* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data (e.g., someone not able to answer the questionnaire because of a psychological condition or an anxiety disorder that is severe).
* Contraindication for routine blood draws (e.g., severe anemia, hemophilia, etc)

Primary outcomes:
measure: Prevalence of Symptomatic Infection
timeFrame: 1 year
measure: Prevalence of Subclinical Infection
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Luca Schifanella, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00366483: Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Lecozotan SR Administered Orally to Healthy Young and Elderly Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Keywords: healthy young volunteers
healthy elderly volunteers
Alzheimer's disease
5HT1A antagonist
Health
Pharmacokinetics
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2006-08-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of lecozotan SR in healthy young and elderly subjects.


Eligibility criteria: Inclusion Criteria: -Young subjects: Men aged 18 to 45 years. -Elderly subjects: Men and women ≥ 65 years of age. -Body mass index in the range of 18 to 30 kg/m2 and body weight ≥ 50 kg. -Healthy as determined by the investigator.

Exclusion Criteria: -History of any neuropsychiatric disorder. -History of drug or alcohol abuse.

Primary outcomes:
measure: The incidence of adverse events and adverse reactions will be calculated. The safety variables (vital signs, ECG parameters, and routine laboratory tests) and PK parameters will be measured throughout study period.
Secondary outcomes:
measure: Pharmacokinetic analysis after single and multiple dosing
Other outcomes:
Locations:
city: Paris
country: France
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For France, infomedfrance@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06689683: Fluoroscopy Activation Interval in SWL
Official title: Comparison of Two Different Fluoroscopy Activation Intervals in Shock Wave Lithotripsy: a Prospective Randomised Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kidney Calculi
Keywords: kidney stone
shock wave lithotripsy
radiation
Lead sponsor: Lütfi Kırdar City Hospital
Sponsor class: OTHER
First posted: 2024-11-14
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Shock wave lithotripsy (SWL) is a noninvasive method widely used as the first step in treating stone disease. This study aimed to reduce radiation exposure to patients and practitioners during SWL sessions by extending the intervals of fluoroscopy controls. The main questions it aims to answer are:

* Will radiation exposure be reduced?
* Will the stone-free status be affected? The researchers will compare the fluoroscopic control intervals of 250 shocks and 500 shocks.

Participants will:

* Take to a maximum of 3 sessions.
* Check once a week
* Group 1 was fluoroscopically monitored every 250 shocks, and Group 2 was fluoroscopically monitored every 500 shocks

Detailed description: SWL works on the principle of focusing on the calculus using ultrasonography or fluoroscopy, transmitting high-energy shock waves from the lithotripter to the calculus and fragmenting it. Fluoroscopic focusing is a commonly used imaging technique that raises concerns about ionizing radiation exposure for patients, technologists, and physicians. Intermittent fluoroscopic monitoring during SWL is widely employed to adjust for patient movement, respiratory movement, and stone displacement within the kidney. However, there is no consensus on the optimal frequency of fluoroscopic monitoring in the literature. This study aims to seek to determine whether increasing the duration between fluoroscopic checks affects the success rate of SWL in achieving stone-free status while reducing radiation exposure to patients.

Eligibility criteria: Inclusion Criteria:

* radiopaque renal pelvic stones smaller than 2 centimeters.

Exclusion Criteria:

* anatomical anomalies, coagulation disorders, non-opaque calculi, active urinary infection and distal obstruction

Primary outcomes:
measure: evaluate The effect of two different fluoroscopic activation intervals on the stone-free rate.
timeFrame: 1 month after the end of treatment
Secondary outcomes:
measure: Secondary endpoints were total fluoroscopy time and complications.
timeFrame: From registration until the 1st month after the end of treatment.
measure: Secondary endpoints were complications.
timeFrame: From registration until the 1st month after the end of treatment.
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Health Science University Kartal Dr. Lütfi Kırdar City Hospital
Study officials:
References:
Clinical trial NCT01633983: Methotrexate for Central Serous Chorioretinopathy Treatment Trial
Official title: Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Central Serous Chorioretinopathy
Keywords: Central Serous Chorioretinopathy
Methotrexate
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2012-07-06
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Detailed description: Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the center of the macula in adults of working age. Though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few short retrospective series of beneficial effect of MTX on CSC were reported recently. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision in a prospective manner.

Eligibility criteria: Inclusion Criteria:

* Central Serous Chorioretinopathy

Exclusion Criteria:

* Pregnancy
* Liver disease
* Kidney disease
* Steroid use

Primary outcomes:
measure: Optical Coherence Tomography indicating the level of central serous detachment
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Hebrew Univercity Medical Center
Study officials:
affiliation: Hadassah Medical Organization
name: Edward Averbukh, MD
role: PRINCIPAL_INVESTIGATOR
References: